WASHINGTON, DC - (NewMediaWire) - September 18, 2015 - Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company specializing in cannabis formulation-based drug development, today announced that accomplished scholar, epidemiologist, and public health physician Allen A. Herman, M.B., Ch.B., Ph.D. has been named as the Chief Medical Officer (CMO) of CBIS. Dr. Herman already serves on the Scientific Advisory Board of CBIS.
Dr. Herman served as a project officer and program director at the National Institute of Health (NIH). For his work in maternal and child health Dr. Herman received the National Institute's Award of Merit. Dr. Herman designed the basis for a nationwide $160 million infant mortality reduction initiative and was the co-director of joint projects between the NIH and the Centers for Disease Control and Prevention (CDC). His work as the scientific director of a $25 million NIH Infant Mortality Reduction research program defined the basis for much of the current community-based maternal and child health work designed to provide a healthy start for families. In addition to his work on maternal and child health, Dr. Herman was a member of the World Mental Health Survey team and helped design, execute, analyze, and publish peer-reviewed scientific papers from the South African Stress and Health Study, the largest mental health survey in Africa.
Dr. Herman was the Advisor to the Hon. Ronald V. Dellums, who served President Bill Clinton as the Chairman of the U.S. Presidential Committee on HIV/AIDS. In this capacity, Dr. Herman, Mr. Dellums and Congresswoman Barbara Lee (the founding co-chair of the Congressional HIV/AIDS Caucus) developed the successful congressional legislation for the "AIDS Marshall Plan for Africa" which formed the basis of the President's Emergency Plan for AIDS Relief (PEPFAR). For his work in HIV/AIDS, Dr. Herman received the 'Heroes in Medicine' award from the International Association of Physicians in AIDS Care.
He was the founding Dean of the Republic of South Africa's National School of Public Health. Dr. Herman also served as scientific advisor to then deputy-president (an now president) of the Republic of South Africa, Jacob Zuma and the South African Minister of Defense in the design and execution of a substantial HIV/AIDS treatment program for the South African National Defense Force. Dr. Herman and Mr. Dellums secured $200 million from Bristol-Myers Squibb, funds used to develop the 'Secure the Future' project, a research and scientific development program for five southern African countries. Dr. Herman served as a Principal Investigator and on the Scientific Advisory Board of 'Secure the Future'.
Dr. Herman will report directly to the President & CEO, Mr. Raymond C. Dabney to assist him in a number of ways, and he will work closely with the Scientific Advisory Board and individual drug development leaders. He will be directly responsible to Mr. Dabney for the management of the growing portfolio of international drug development programs of CBIS. This work will involve the development of a secure and robust template for drug development that will ensure that safety, efficacy, and effectiveness of new drugs reach the high levels set by the US Federal Drug Administration, drug regulatory bodies in Canada, Europe and drug regulatory bodies in other critical regions. Dr. Herman will also design and maintain a patient-centered outcomes research program that will be built as part of the Patient Access Center (PAC). This program will continue its critical mission of providing a forum for patients with multiple chronic conditions and the data from this program will inform in the design and development of new drug development programs. He will review existing protocols and collaborate in the design, development, and implementation of new drug development protocols. He will also track and monitor the multiple international drug development programs the company has underway, and work with drug development regulatory bodies to ensure compliance with development. Because of Dr. Herman's has vast expertise in international healthcare systems, healthcare management, program design and implementation, and health professional continuing education he will be a valuable asset to Mr. Dabney. Dr. Herman will report regularly to Mr. Dabney and he will ensure that the reports to the public of the Company's scientific progress and accomplishments are timely, coherent, and clear
"This is an exciting opportunity for me to work closely with Mr. Dabney and the CBIS Team. During my time working with Mr. Dabney on a number of projects, he has impressed me with his great facility to combine great attention to detail with a vision for what can be achieved. A quick understanding of complexity and a way to make programs functional marks his leadership. I look forward to assisting the team with a strong research and policy-based tracking system focused on developing promising pharmaceutical products and delivery mechanisms that have the potential to help many patients with many critical ailments around the world," said Dr. Herman. "The promise is as huge as the need, worldwide."
"We now have yet another cornerstone that will help us take the company to the next level. Dr. Herman will join our well-respected and accomplished team of pharmaceutical drug development specialists. We are growing so fast that Dr. Herman's main duty will be to report our international activities as one, so the team is up to speed and working closely as one unit as we grow exponentially," stated, Mr. Dabney.
Please click here to review Dr. Herman's full CV:
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.